40 results
8-K
EX-99
GSTC
GlobeStar Therapeutics Corp
6 May 21
AngioSoma, Inc. Adds Brooke Greenwald As Chief Marketing Officer
5:27pm
success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility … ,” “expects,” “anticipate” or similar expressions. This news release speaks as of the date first set forth above and the company assumes no responsibility
8-K
EX-99
GSTC
GlobeStar Therapeutics Corp
22 Jun 23
Globestar Therapeutics Enters into Mou with Advanced Innovative Partners to Develop Clinical Studies for Multiple Sclerosis Treatment
5:18pm
will lead the effort, contribute related rights to Project Amethyst™, and have primary responsibility for financing, supply chain, manufacturing, and sales … of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information
S-1
EX-14
GSTC
GlobeStar Therapeutics Corp
3 Nov 10
IPO registration
12:00am
The Company strives to provide each employee with a safe and healthy work environment. Each employee has responsibility for maintaining a safe … seems unethical or improper, it probably is.
CLARIFY YOUR RESPONSIBILITY AND ROLE. In most situations, there is shared responsibility. Are your
8-K
EX-99
GSTC
GlobeStar Therapeutics Corp
6 May 21
AngioSoma, Inc. Adds Brooke Greenwald As Chief Marketing Officer
5:27pm
success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included … ” or similar expressions. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information
CORRESP
GSTC
GlobeStar Therapeutics Corp
11 Feb 11
Correspondence with SEC
12:00am
to delegated authority, in declaring the filing effective, does not relieve the registrant from its full responsibility for the adequacy and accuracy
8-K
EX-99
4fmu5 kwn9
25 Feb 21
Angiosoma and its Subsidiary Somaceuticals Announce Amended and Restated Execution of Global License for Multiple Sclerosis Patent
5:30pm
8-K
EX-99
5js i75dmk8dx
12 Oct 21
Regulation FD Disclosure
8:27am
CORRESP
10rj8q2y3n58co6xf3
8 Feb 11
Correspondence with SEC
12:00am
8-K
EX-99
l311in7l1 pz76n3ltwx
24 Aug 20
SomaCeuticals Acquires License for Treatment of Multiple Sclerosis
5:01pm
8-K
EX-99
sn9e8skhd9wren6r s3
6 May 21
AngioSoma, Inc. Adds Brooke Greenwald As Chief Marketing Officer
5:27pm
S-1
EX-3
fwbgg7ptymo kgu
3 Nov 10
IPO registration
12:00am
8-K
EX-99
3s1l 2tbozwf4mynwq0t
6 May 21
AngioSoma, Inc. Adds Brooke Greenwald As Chief Marketing Officer
5:27pm
8-K
EX-99.1
shdhwvritig fee4e
23 Oct 19
AngioSoma, Inc. Announces Settlement of Litigation
11:28am
8-K
EX-99
ks5xkc4 yugtumjysiuk
19 Aug 19
Regulation FD Disclosure
9:41pm
8-K
EX-99
zrcnafxgj7b36mzomi
4 Oct 21
Regulation FD Disclosure
8:48am
8-K
EX-99
8swq4i
9 Dec 20
SomaCeuticals Moving Forward With Treatment of Multiple Sclerosis
12:00am
8-K
EX-99
hujqk7q2kf7nlq wl2f
16 Apr 21
AngioSoma, Inc. Is Pleased to Welcome William Farley to Its Board of Directors
4:20pm
8-K
EX-99
y0z8iab
13 Nov 23
Other Events
12:32pm